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Abstract
Background: This study aimed to estimate the rate of HER-2/neu (c-erbB2) immunohistochemical 
overexpression in different histological types of breast cancer found in the middle Euphrates region of Iraq, 
a region that was exposed to high levels of depleted uranium. HER-2/neu (c-erbB2) overexpression was 
correlated with common clinicopathological parameters such as age, grade, stage, tumor size and lymph node 
involvement to determine if any particular biomarker for exposure to depleted uranium could be found in 
the tumor samples from this region. Materials and Methods: The present investigation was performed 
over a period starting from September 2007 to June 2008. Formalin-￿  xed, paraf￿  n-embedded blocks from 
90 patients with breast cancer were included in this study. A group of 25 patients with benign breast lesions 
(￿  broadenoma) was included as a comparative group, and 20 breast tissue sections were used as controls. Labeled 
streptavidin-biotin (LSAB) complex method was employed for immunohistochemical detection of HER-2/neu. 
Results: HER-2/neu immuno-expression was positive in 67.8% of breast cancer, while it was negative in all 
benign breast lesions (￿  broadenoma) (P < 0.05). HER-2/neu immunostaining was signi￿  cantly associated with 
histological type and recurrence of breast cancer (P < 0.05). It was positively correlated with tumor grade, but 
this ￿  nding was not signi￿  cant (P > 0.05). Conclusion: Based upon the ￿  ndings of this study, it can be concluded 
that HER-2/neu overexpression plays an important role in the pathogenesis of breast cancer and is associated 
with a worse prognosis. The ￿  ndings indicate that in regions exposed to high levels of depleted uranium, HER-2/
neu overexpression is high, but its correlation with age, grade, stage, tumor size, and lymph node involvement 
is similar to studies that have been conducted on populations not exposed to depleted uranium. 
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Background
Breast carcinoma is the commonest malignant tumor and the 
leading cause of cancer death in women, with more than one 
million new cases occurring worldwide annually.[1] It is well 
known that proto-oncogenes and tumor suppressor genes 
are two types of genes that play a key role in the regulation 
of cell growth and differentiation. Hence, any alteration in 
one or more of these genes appears to play an important role 
in the pathogenesis of most human malignancies.[2] HER-2/
neu proto-oncogene amplification and/or overexpression is 
one of the most important alterations seen in breast cancer. 
The HER-2/neu proto-oncogene (also called c-erbB2) is 
located on chromosome 17q11[3–5] which encodes for p185, a 
transmembrane glycoprotein with tyrosine kinase activity that 
belongs to the family of epidermal growth factor receptors.[4] 2 2
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HER2/neu proto-oncogene is amplified and/or overexpressed 
in approximately 25–30% of invasive breast cancers.[5,6] An 
association has been found to exist between amplification and/
or overexpression of HER-2/neu and a wide variety of different 
clinical and pathological features of breast carcinoma. From 
a clinical point of view, HER-2/neu receptor has become an 
important target for antibody-based therapy with trastuzumab 
(Herceptin). 
In Iraq, where the population was exposed to high levels of 
depleted uranium following the first and second Gulf Wars, 
breast cancer is the most common tumor type in females.[7] 
Over the last ten years, there has been a three-fold increase in 
the incidence of breast cancer,[8] with most of this increase being 
attributed to a particularly aggressive type of the cancer.[9,10] 
This finding inspired an investigation of Her2/neu expression 
in a series of Iraqi women with breast cancer to see whether 
any differences in Her2/neu expression, in correlation with 
tumor characteristics, could be found in a population exposed 
to depleted uranium. 
Materials and Methods
Ninety specimens of formalin-fixed, paraffin embedded 
breast cancer tissue, collected from breast cancer patients 
over a period from September 2007 to June 2008 were 
included in this study. All cases were collected from major 
hospitals and private laboratories in Kufa district area 
(located in the middle of Iraq). The age range of patients 
was 21 to 70 years, with a mean age of 48.8 years. A group 
of 25 patients with benign breast lesions (fibroadenoma) 
was included as a comparative group and 20 normal breast 
tissue sections were included as controls. Confirmation of 
histopathological diagnosis, grade and stage of tumor was 
carried out after reviewing all slides before proceeding to 
the immunohistochemical approach. Tissue sections with 
a thickness of 5-µ were taken from the formalin-fixed, 
paraffin embedded blocks for immunohistochemistry. 
Labeled streptavidin-biotin (LSAB) method was employed 
for immunohistochemical detection of HER-2/neu 
using Hercep Test Kit (K5204 Dako Co.). The intensity 
of HER-2/neu cell membrane stain was classified into 
score 0 (negative; no stain is observed or faint membrane 
staining presents in less than 10% of tumor cells), score 
1+ (negative; a faint/barely perceptible membrane staining 
was detected in more than 10% of tumor cells; these cells 
exhibit incomplete membrane staining), score 2+ (weakly 
positive; a weak to moderate complete membrane staining 
was observed in more than 10% of tumor cells) and score 
3+ (strongly positive; a strong complete membrane staining 
was observed in more than 10% of tumor cells).[11] All 
biopsies were classified according to the modified Bloom 
Richardson Grading System into three grades: Grade 
I, Grade II and Grade III. The results were statistically 
evaluated with a Chi-squared test (at a significant level of 
<0.05) and correlation-regression analysis (at significant 
level of R = 0.3) using SSPS software. The study received 
ethical approval from the Research Ethics Committee of the 
Middle Euphrates Centre for Cancer Research and followed 
the Tenets of the Declaration of Helsinki.
Results
HER-2/neu immuno-expression was positive in 67.8% of 
breast cancer cases and negative in all sections of the normal 
breast tissue and benign breast lesions (fibroadenomas) with 
significant differences among these groups (P < 0.05) [Table 
1]. HER-2/neu overexpression was detected in 73.2% of 
invasive ductal carcinoma (IDC) cases and in 12.5% of invasive 
lobular carcinoma. The difference was statistically significant 
(P < 0.05).
Overexpression of HER-2/neu was detected in 65.6% of those 
with pure invasive ductal carcinomas; all of them were of a 
nonspecific type. A 94.4% of invasive ductal carcinoma with an 
in situ comedo component (DCIS) and 100% of invasive ductal 
carcinoma with overlying Paget’s disease were HER-2/neu 
positive with a significant difference (P < 0.05) in comparison 
with pure invasive ductal carcinomas [Table 1]. 
There was a significant difference between the intensity of 
HER-2/neu overexpression and the histological type of breast 
cancer (P < 0.05) [Table 2]. HER-2/neu overexpression was 
detected in 70.6% of Grade II and 69.0% of Grade III breast 
cancer samples, while none of Grade I showed HER-2/neu 
overexpression [Table 1]. There was no significant difference 
in HER-2/neu overexpression between Grade II and Grade 
III of breast cancer (P > 0.05), but in comparison with Grade 
I a significant difference was noticed (P < 0.05). HER-2/neu 
overexpression was highly correlated with grade of tumor (R 
= 0.96), indicating that HER-2/neu-positive breast cancers 
are biologically aggressive. No statistically significant difference 
in the correlation between the intensity of HER-2/neu 
immunostaining and histological grade was found (P >0.05) 
[Table 2]. 
In addition, a higher detection rate of HER-2/neu overexpression 
was noticed in recurrent breast cancer than primary lesions 
(86.2% and 59.1%, respectively) with a significant difference 
(P < 0.05) [Table 1]. No statistically significant differences 
between HER-2/neu overexpression and tumor size, tumor 
stage, lymph node involvement, and age of breast cancer 
patients were found (P > 0.05) [Table 1].3 3
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Table 1: HER-2/neu(C-ErbB-2) overexpression and histological characteristics 
Parameters  Total    c-ErbB-2 protein overexpression   P value  R test
  No. of pati  ents  (Negati  ve)    (Positi  ve)
Benign ￿  broadenoma  25  25 (100)    0 (-)  <0.05
Normal breast tissue   20  20 (100)    0 (-)
Malignant cases   90  29 (32.2)    61(67.8)
Histological type
Ductal carcinoma**  82   22 (26.8)    60 (73.2)     <0.05
Lobular carcinoma  8  7 (87.5)    1 (12.5)
**including 
IDC + DCIS  18  1 (3.6 )    17 (94.4)
IDC + Paget￿s  3  0    3 (100)
Grade
I  2  2 (100)    0 (-)  >0.05  0.96
II  17  5 (29.4)    12 (70.6)
III  71  22 (31.0)    49 (69.0)
Tumor size
≤ 2 cm.  3  0 (-)    3 (100)  >0.05
2￿5 cm.  43  18 (41.8)    25 (58.2)
>5 cm.  44  11 (25)    33 (75)
Tumor stage
Stage I  5  3( 60)    2 (40)  >0.05  0.07
Stage II  23  5 (21.7)    18 (78.3)
Stage III  41  13 (31.7)    28 (68.3)
Stage IV  3  2 (66.7)    1 (33.3)
Age 
<50  46  15 (32.6)    31 (67.4)  >0.05
>/50  44  14 (31.8)    30 (68.2)
Axillary lymph nodes
Negative  22  10 (45.5)    12 (54.5)   >0.05
Positive  50  13 (26)    37 (74)
Tumor recurrence
Recurrent  29  4 (13.8)    25 (86.2)  <0.05
Primary  61  25 (40.9)    36 (59.1)
Figures in parentheses are in percentage
Table 2: The intensity of HER-2/neu(C-ErbB-2) overexpression and histological characteristics
Parameters  Total           c-ErbB-2 protein overexpression intensity    P value  R test
  No. of pati   ents  0  1+ 2+ 3+
Histological type
IDC  61 9 12  20  20  <0.05 
ILC  8 3 4 1 0
IDC+DCIS  18 0  1 10 7
IDC+  Paget￿s  3 0 0   0 3
Grade
I  2 0 2 0 0  <0.05  0.94
II  17  3 2 6 6
III  71 4 18  24  25
Tumor stage
Stage  I  5 2 1 1 1  >0.05
Stage  II  23  0 5 9 9
Stage  III  41 3 10  16  12
Stage  IV  3 0 2 1 0
Tumor recurrence
Recurrent  29 1  3 12  13  >0.05
Primary  61 11 14 19 17 
Discussion
Depleted uranium levels were estimated to be around 320–800 
tons in the aftermath of the first Gulf war in 1991 with further 
comparable levels occurring in 2003.[8] Since the targets were 
always in heavily populated areas in the middle and south of 
Iraq, the extent of exposure on individuals was extensive but 
has been very hard to document accurately.[8] 
This study showed that HER-2/neu overexpression was 
completely absent in both normal breast tissue and benign 
lesion (fibroadenomas) sections. The percentage of HER-2/4 4
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neu overexpression in malignant breast lesions is disputed in 
our study as it ranges from 12.5% to 100%, but the finding is 
that HER-2/neu overexpression appears to be a biomarker for 
malignant breast tissue and does not play any role in the benign 
(fibroadenomas) breast lesions. This observation confirms 
the results of many previous studies that reached the same 
conclusion.[11–12]
Indeed, our study reported HER-2/neu overexpression in 
67.8% out of 90 breast cancer cases [Figure 1a]. This result 
is significantly higher than findings reported elsewhere.[13] 
Furthermore, most of the ductal carcinoma cases were purely 
invasive ductal carcinomas of nonspecific type (74.4%) that 
showed significant HER-2/neu overexpression (65.6%). 
This provides more evidence of the hypothesis that aggressive 
tumors seem to show significant HER-2/neu overexpression 
and demonstrates the association between the nature of the 
biological expression of HER-2/neu by the tumor and its degree 
of malignancy since it has been argued that nonspecific type 
ductal carcinomas are the most aggressive variants of breast 
cancer.[14] The current study also demonstrated that 12.5% 
of lobular carcinoma cases exhibited HER-2/neu expression 
[Figure 1d].
From the above results, a significant difference in HER-2/
neu overexpression was observed between invasive ductal 
and lobular carcinoma (P < 0.05). This high discrepancy in 
HER-2/neu overexpression between invasive ductal and lobular 
carcinoma suggests that invasive lobular carcinomas are both 
morphologically and biologically different from invasive ductal 
carcinomas. However, further studies are required to provide a 
more definitive answer. All 18 cases of IDC with comedo-type in 
situ component showed HER-2/neu overexpression [Figure 1b]. 
The finding that HER-2/neu expression is seen more frequently 
in DCIS than in invasive carcinoma implicates that HER-2/
neu signaling pathway is playing a critical role in the early 
stages of breast tumorogenesis. HER-2/neu overexpression 
was seen in all cases of both the invasive ductal carcinoma and 
Paget’s disease components, when both components were seen 
simultaneously [Figure 1c].
HER-2/neu overexpression of low intensity (score 1+, 
considered as negative) was observed more frequently in 
ILC (50%), while weak to moderate intensity of HER-2/neu 
overexpression (score 2+) occurred more frequently in Invasive 
Ductal Carcinoma (IDC) + Ductal Carcinoma with an in situ 
comedo component (DCIS) (55.5%). High intensity of HER-2/
neu overexpression (score 3+, considered as strong positive) 
was reported more frequently in Paget’s disease (100%). These 
results suggest that the intensity of HER-2/neu overexpression 
is well correlated with histopathological type. Previous studies 
have shown faint or absent HER-2/neu overexpression in 
lobular carcinoma[15] and a strong positive score (score +3) in 
all cases of Paget’s disease.[16]
The findings of this study show that a high incidence of samples 
of IDC with in-situ component (55.5%) were moderately 
stained (score +2). This compares with the findings of Lan 
et al.,[17] who examined the prevalence of c-erbB-2 gene 
amplification in moderately stained (score +2) Taiwanese 
specimens using IHC and found a higher prevalence of HER-2 
overexpression (44.4%) than that found in similar studies from 
Western countries (13%–23%).[18-19]
This study found no significant association between HER-2/neu 
overexpression and age of the patients [Table 1], which concurs 
with a previous study.[16] A high proportion of HER-2/neu 
overexpression was seen in moderately and poorly differentiated 
cases of breast cancer, while a lower proportion of HER-2/neu 
expression was reported in cases of well differentiated breast 
cancer. HER-2/neu expression appears to be well correlated 
with tumor grade (R = 0.96). Immunohistochemical analysis 
showed HER-2/neu overexpression to be higher in recurrent 
than in primary cases of tumor. This finding was significant (P 
< 0.05). These results reflect the significant role of HER-2/neu 
overexpression in increasing the risk of local recurrence.[3]
It has been well documented that positive HER/2 breast cancer 
patients have good prognosis as they respond well to the blocking 
effect of these receptors by anti-HER/2 receptor antibody using 
monoclonal (Herceptin) drug that plays a role in the regression 
of the tumor size and prevention of recurrence.[6] All the patients 
in this study were advised to follow this treatment. The driving 
a b
d c
Figure 1: (a) Invasive ductal carcinoma, (!) showing strong 
complete cytoplasmic membrane staining of score 3+ (40x). 
(b) Insitu ductal carcinoma of comedo type, (!) showing strong 
complete cytoplasmic membrane staining of score 3+”positive   
(10x). (c) Paget’s disease, (!) showing strong complete cytoplasmic 
membrane staining of score 3+ (40x). (d) Invasive lobular carcinoma, 
pleomorphic type, (!) showing moderate complete membrane 
staining of score 2+ (40x)5 5
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factor for the increased expression of HER-2/neu to the level of 
68% compared to general expression of 30% might be due to 
some underlying genetic factors, although other environmental 
factors cannot be excluded. Further investigations are needed 
to ascertain the extent of the effect of depleted uranium and 
the types of mutations noted in the overexpressed oncogene 
before any final conclusions can be reached
Conclusion
Despite the three-fold increase of all types of breast cancer 
in Iraq due to long-term exposure to depleted uranium, this 
heightened exposure does not appear to be correlated with 
HER-2/neu overexpression. Differences may become evident 
with time and as mutations are passed to future generations. 
Further longitudinal studies and the use of techniques such 
as microarrays are required to investigate whether any effect 
of depleted uranium does manifest in the pathology of breast 
cancer. 
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